Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)
Not Applicable
Completed
- Conditions
- Allergic Asthma
- Interventions
- Drug: Single corticosteroid inhalers and Singulair
- Registration Number
- NCT00421018
- Lead Sponsor
- Karolinska Institutet
- Brief Summary
The purpose of this study is to determine whether use of exhaled NO (nitric oxide) to regulate the anti-inflammatory treatment leads to increased asthma-related quality of life in patients with allergic asthma
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 187
Inclusion Criteria
- Age 18-64
- Clinical diagnosis of Asthma
- Glucocorticoid treatment > 6 months.
- Verified Allergy
- Read and speak Swedish
Exclusion Criteria
- Smoking
- Current regular treatment with long-acting beta2-agonist
- Treatment with Singulair only or in combination with glucocorticoids
- Taking part in other research study
- Pregnancy or breast-feeding
- Unstable Asthma
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Symptom-guided group Single corticosteroid inhalers and Singulair Anti-inflammatory treatment is guided conventionally according to symptoms and beta-2-agonist use. FeNO-guided group Single corticosteroid inhalers and Singulair Anti-inflammatory treatment is guided according to the level of exhaled nitric oxide
- Primary Outcome Measures
Name Time Method Mini-AQLQ (Asthma-Related Quality of Life) 1 year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Runby Primary Health Care Center
🇸🇪Upplands Väsby, Sweden